Next-Generation Formulation Infrastructure for HIV Therapy

SCF BIOTECH Systems Therapeutics is advancing a precision formulation platform for Biktarvy-class antiretroviral therapy through the development of SCF-engineered excipient APIs.

This technology transforms traditional excipients into functional pharmacokinetic stabilizers, enabling more consistent drug exposure across diverse patient populations while preserving the validated antiviral mechanisms of existing therapies.

The platform is designed to enhance the long-term reliability of current gold-standard HIV regimens—while creating a scalable formulation architecture for future therapeutic innovations.

The Clinical Context

Modern antiretroviral therapy has achieved extraordinary virologic control. Regimens such as Biktarvy combine:

• Integrase strand transfer inhibition
• Reverse transcriptase inhibition
• Targeted intracellular prodrug delivery

These mechanisms align with the core pharmacologic principles of targeted drug action, pharmacokinetic optimization, metabolic efficiency, resistance prevention, and safety.

Despite this progress, HIV therapy remains lifelong treatment, often extending over several decades. Over time, physiological changes introduce variability in drug absorption and intracellular exposure.

These include:

• Aging-related gastrointestinal changes
• Metabolic disorders and mitochondrial dysfunction
• Polypharmacy in aging populations
• Chronic inflammatory conditions

These factors rarely produce immediate treatment failure but can introduce long-term pharmacokinetic variability, potentially reducing therapeutic robustness over decades of therapy.

The SCF Solution: Excipient APIs

SCF BIOTECH Systems introduces a new formulation paradigm: Excipient APIs.

Unlike conventional excipients, which primarily serve passive roles, SCF excipient APIs are mechanistically engineered formulation components designed to stabilize pharmacokinetics without altering the active pharmaceutical ingredients.

Key characteristics:

• Pharmacokinetically targeted
• Mechanistically justified
• Pharmacologically inert
• Compatible with existing APIs
• Regulatory-aligned for reformulation pathways

These excipients function as precision pharmacologic infrastructure, improving systemic reliability while preserving the therapeutic intent of the original regimen.

Engineering the SCF Excipient Infrastructure

The SCF platform constructs a functional excipient layer around Biktarvy-class APIs.

Each excipient contributes a defined pharmacokinetic role.

Together these components form a precision pharmacokinetic envelope designed to maintain consistent drug exposure across diverse physiological conditions.

Designed for Diverse HIV Populations

One of the major advantages of SCF excipient engineering is the ability to adapt formulations for specific patient cohorts while preserving the same APIs.

Pediatric Patients

• Safety-optimized excipient profiles
• GI-compatible dissolution kinetics
• Reduced metabolic burden

Aging HIV Population

• Bile-independent absorption stabilization
• Mitochondrial metabolic support
• Improved oxidative stability

Patients with Metabolic Comorbidities

• Stabilized intracellular pharmacokinetics
• Improved lipid-phase dissolution
• Reduced trough variability

Polypharmacy Populations

• Transporter-neutral formulation design
• Minimal drug-drug interaction potential
• Stable GI absorption profiles

Platform Value for Partners

Pharmaceutical Innovators

SCF excipient APIs enable:

• Lifecycle extension of existing therapies
• Population-specific product variants
• Global market resilience through climate-stable formulations

Clinical Partners

For physicians and clinical investigators, the platform aims to deliver:

• More consistent pharmacokinetics across patient populations
• Reduced long-term variability in drug exposure
• Enhanced reliability for lifelong therapy

Strategic Investors

The SCF platform represents a scalable formulation technology applicable across multiple therapeutic areas, including:

• Antiviral therapies
• Oncology combination regimens
• Chronic metabolic diseases

By focusing on pharmacokinetic infrastructure rather than molecular replacement, the platform offers lower development risk with significant lifecycle expansion potential.

Regulatory Strategy

The SCF excipient API platform is designed for alignment with established regulatory frameworks.

The primary pathway for development is the FDA 505(b)(2) reformulation pathway, which allows sponsors to rely partly on existing clinical data while demonstrating comparability through pharmacokinetic bridging studies.

This strategy enables efficient translation from formulation innovation to clinical deployment.

Toward the Future of HIV Therapy

Antiretroviral therapy has transformed HIV into a manageable chronic condition. The next stage of innovation will focus on long-term pharmacologic reliability and compatibility with future cure-oriented interventions.

SCF BIOTECH Systems is developing excipient API engineering as the pharmacokinetic infrastructure layer for next-generation HIV therapeutics.

By stabilizing systemic drug exposure across diverse patient populations, this platform supports the evolution of HIV treatment toward more durable, personalized, and ultimately curative therapeutic strategies.

Partnership and Collaboration

SCF BIOTECH Systems Therapeutics is actively seeking collaboration with:

• Pharmaceutical innovators
• Contract development and manufacturing organizations
• Clinical research institutions
• Strategic investment partners

For partnership inquiries and scientific collaboration, please contact:

SCF BIOTECH Systems Therapeutics — Strategic Partnerships Division